A comparison of pneumonitis incidence rates between patients who received CTLA-4 inhibitors and those who did not revealed that, out of 1,198 patients treated with CTLA-4 inhibitors, 38 (3.17%) experienced any-grade pneumonitis. This evidence concerns the gene CTLA4 and pneumonitis.